PGC-1α, A Potential Therapeutic Target for Early Intervention in Parkinson’s Disease
暂无分享,去创建一个
Manuel B. Graeber | Howard J. Federoff | Aron C. Eklund | Ullrich Wüllner | Jean-Christophe Rochet | Thomas G. Beach | Jeffery M. Vance | Yanli Zhang-James | Peter Riederer | Michael A. Hauser | Frank A. Middleton | A. Young | C. Adler | F. Middleton | A. Eklund | J. Vance | M. Hauser | S. Mandel | J. Hedreen | L. Moran | M. Graeber | S. Papapetropoulos | P. Riederer | J. Locascio | T. Beach | E. Grünblatt | J. Rochet | H. Federoff | Y. Zhang‐James | M. Youdim | U. Wüllner | C. Scherzer | Renee M. Miller | I. Cantuti-Castelvetri | Zhixiang Liao | R. Davis | Anne B. Young | Edna Grünblatt | Spyridon Papapetropoulos | Ippolita Cantuti-Castelvetri | Charles H. Adler | Bin Zheng | Kristen A. Lesniak | Sarah S Roderick | Marla L. Watt | Peter D. Kim | Moussa B. Youdim | Joseph J. Locascio | Bin Zheng | Zhixiang Liao | Sarah S. Roderick | Linda B. Moran | Silvia A. Mandel | Richard L. Davis | John C. Hedreen | Clemens R. Scherzer | I. Cantuti‐Castelvetri | I. Cantuti-castelvetri | Zhang-James Yanli | Y. Zhang-James
[1] Jean YH Yang,et al. Bioconductor: open software development for computational biology and bioinformatics , 2004, Genome Biology.
[2] Fabienne C. Fiesel,et al. PINK1/Parkin-mediated mitophagy is dependent on VDAC1 and p62/SQSTM1 , 2010, Nature Cell Biology.
[3] Jiandie D. Lin,et al. Transcriptional coactivator PGC-1 alpha controls the energy state and contractile function of cardiac muscle. , 2005, Cell metabolism.
[4] M. Daly,et al. PGC-1α-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes , 2003, Nature Genetics.
[5] Clemens R Scherzer,et al. Yeast genetics targets lipids in Parkinson's disease. , 2004, Trends in genetics : TIG.
[6] D. Dickson,et al. Evidence in favor of Braak staging of Parkinson's disease , 2010, Movement disorders : official journal of the Movement Disorder Society.
[7] M. Vila,et al. MPTP as a Mitochondrial Neurotoxic Model of Parkinson's Disease , 2004, Journal of bioenergetics and biomembranes.
[8] J. Levin,et al. Pesticide/Environmental Exposures and Parkinson's Disease in East Texas , 2008, Journal of agromedicine.
[9] J. Growdon,et al. Molecular markers of early Parkinson's disease based on gene expression in blood , 2007, Proceedings of the National Academy of Sciences.
[10] Pablo Tamayo,et al. Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[11] C. Tanner,et al. Parkinsonian signs and substantia nigra neuron density in decendents elders without PD , 2004, Annals of neurology.
[12] B. de Strooper,et al. Mitochondria dysfunction and neurodegenerative disorders: cause or consequence. , 2010, Journal of Alzheimer's disease : JAD.
[13] Isidre Ferrer,et al. Evidence of Oxidative Stress in the Neocortex in Incidental Lewy Body Disease , 2005, Journal of neuropathology and experimental neurology.
[14] P M Pattany,et al. Proton MR spectroscopy of the brain in 14 patients with Parkinson disease. , 1995, AJNR. American journal of neuroradiology.
[15] W. Rocca,et al. When does Parkinson disease start? , 2010, Archives of neurology.
[16] Robert E Burke,et al. A critical evaluation of the Braak staging scheme for Parkinson's disease , 2008, Annals of neurology.
[17] G. Lenzi,et al. Increased expression of dopamine receptors on lymphocytes in Parkinson's disease , 1999, Movement disorders : official journal of the Movement Disorder Society.
[18] Todd B. Sherer,et al. Chronic systemic pesticide exposure reproduces features of Parkinson's disease , 2000, Nature Neuroscience.
[19] J. Langston,et al. Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. , 1983, Science.
[20] R. Jensen,et al. Expression profiling of substantia nigra in Parkinson disease, progressive supranuclear palsy, and frontotemporal dementia with parkinsonism. , 2005, Archives of Neurology.
[21] K. Jellinger,et al. Critical evaluation of the Braak staging scheme for Parkinson's disease , 2010, Annals of neurology.
[22] C. Adler,et al. Reduced striatal tyrosine hydroxylase in incidental Lewy body disease , 2008, Acta Neuropathologica.
[23] C. Blyth. On Simpson's Paradox and the Sure-Thing Principle , 1972 .
[24] S. Mandel,et al. Gene expression profiling of parkinsonian substantia nigra pars compacta; alterations in ubiquitin-proteasome, heat shock protein, iron and oxidative stress regulated proteins, cell adhesion/cellular matrix and vesicle trafficking genes , 2004, Journal of Neural Transmission.
[25] H. Braak,et al. Invited Article: Nervous system pathology in sporadic Parkinson disease , 2008, Neurology.
[26] J. Rochet,et al. Mechanisms of DJ‐1 neuroprotection in a cellular model of Parkinson’s disease , 2008, Journal of neurochemistry.
[27] Sunhong Kim,et al. Mitochondrial dysfunction in Drosophila PINK1 mutants is complemented by parkin , 2006, Nature.
[28] Jiandie D. Lin,et al. Suppression of Reactive Oxygen Species and Neurodegeneration by the PGC-1 Transcriptional Coactivators , 2006, Cell.
[29] L. Wolman,et al. Ultrastructural observations in Parkinsonism , 1969, The Journal of pathology.
[30] Robert M. Silva,et al. CHOP/GADD153 is a mediator of apoptotic death in substantia nigra dopamine neurons in an in vivo neurotoxin model of parkinsonism , 2005, Journal of neurochemistry.
[31] Christoph Handschin,et al. Metabolic control through the PGC-1 family of transcription coactivators. , 2005, Cell metabolism.
[32] M. Berridge,et al. Characterization of the cellular reduction of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT): subcellular localization, substrate dependence, and involvement of mitochondrial electron transport in MTT reduction. , 1993, Archives of biochemistry and biophysics.
[33] A. Lees,et al. Ageing and Parkinson's disease: substantia nigra regional selectivity. , 1991, Brain : a journal of neurology.
[34] K. Jellinger. A critical evaluation of current staging of alpha-synuclein pathology in Lewy body disorders. , 2009, Biochimica et biophysica acta.
[35] Todd B. Sherer,et al. Mechanism of Toxicity in Rotenone Models of Parkinson's Disease , 2003, The Journal of Neuroscience.
[36] J. Castle,et al. An integrative genomics approach to infer causal associations between gene expression and disease , 2005, Nature Genetics.
[37] L. Moran,et al. Whole genome expression profiling of the medial and lateral substantia nigra in Parkinson’s disease , 2006, Neurogenetics.
[38] H. Park,et al. Protective effect of histamine H2 receptor antagonist ranitidine against rotenone-induced apoptosis. , 2009, Neurotoxicology.
[39] R. Swerdlow,et al. Complex I deficiency in Parkinson's disease frontal cortex , 2008, Brain Research.
[40] M. Beal,et al. Mitochondrial biology and oxidative stress in Parkinson disease pathogenesis , 2008, Nature Clinical Practice Neurology.
[41] F. Benes,et al. Gene expression profiling of substantia nigra dopamine neurons: further insights into Parkinson's disease pathology. , 2009, Brain : a journal of neurology.
[42] C. Marsden,et al. Indices of oxidative stress and mitochondrial function in individuals with incidental Lewy body disease , 1994, Annals of neurology.
[43] H. Braak,et al. Staging of brain pathology related to sporadic Parkinson’s disease , 2003, Neurobiology of Aging.
[44] S. Lindquist,et al. α-Synuclein Blocks ER-Golgi Traffic and Rab1 Rescues Neuron Loss in Parkinson's Models , 2006, Science.
[45] N. Avadhani,et al. Mitochondrial Import and Accumulation of α-Synuclein Impair Complex I in Human Dopaminergic Neuronal Cultures and Parkinson Disease Brain* , 2008, Journal of Biological Chemistry.
[46] J. C. Greene,et al. Mitochondrial pathology and apoptotic muscle degeneration in Drosophila parkin mutants , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[47] D. Dickson,et al. Evidence that incidental Lewy body disease is pre-symptomatic Parkinson’s disease , 2008, Acta Neuropathologica.
[48] J. Xie,et al. Parkinson's Disease Brain Mitochondrial Complex I Has Oxidatively Damaged Subunits and Is Functionally Impaired and Misassembled , 2006, The Journal of Neuroscience.
[49] D. Mash,et al. Multiregional gene expression profiling identifies MRPS6 as a possible candidate gene for Parkinson's disease. , 2006, Gene expression.
[50] C. Tanner,et al. Nongenetic causes of Parkinson's disease. , 2006, Journal of neural transmission. Supplementum.
[51] M. Frosch,et al. Effects of gender on nigral gene expression and parkinson disease , 2007, Neurobiology of Disease.
[52] J. Rochet,et al. Methionine sulfoxide reductase A protects dopaminergic cells from Parkinson's disease-related insults. , 2008, Free radical biology & medicine.
[53] V J Cunningham,et al. Cortical dysfunction in non-demented Parkinson's disease patients: a combined (31)P-MRS and (18)FDG-PET study. , 2000, Brain : a journal of neurology.
[54] D. Dickson,et al. Incidental Lewy body disease and preclinical Parkinson disease. , 2008, Archives of neurology.
[55] Robert Hill,et al. Low platelet mitochondrial complex I and complex II/III activity in early untreated parkinson's disease , 1995, Annals of neurology.
[56] A. Levey,et al. Loss of apolipoprotein E receptor LR11 in Alzheimer disease. , 2004, Archives of neurology.
[57] S. Lindquist,et al. α-Synuclein is part of a diverse and highly conserved interaction network that includes PARK9 and manganese toxicity , 2009, Nature Genetics.
[58] A. Eklund,et al. GATA transcription factors directly regulate the Parkinson's disease-linked gene α-synuclein , 2008, Proceedings of the National Academy of Sciences.
[59] T. Klockgether,et al. Transcriptional changes in multiple system atrophy and Parkinson's disease putamen , 2006, Experimental Neurology.
[60] L. Hedges,et al. Fixed- and random-effects models in meta-analysis. , 1998 .
[61] B. Spiegelman,et al. A fundamental system of cellular energy homeostasis regulated by PGC-1α , 2007, Proceedings of the National Academy of Sciences.
[62] Jill P. Mesirov,et al. GSEA-P: a desktop application for Gene Set Enrichment Analysis , 2007, Bioinform..
[63] Mads Thomassen,et al. Gene expression meta-analysis identifies chromosomal regions and candidate genes involved in breast cancer metastasis , 2008, Breast Cancer Research and Treatment.
[64] F. Middleton,et al. Transcriptional analysis of multiple brain regions in Parkinson's disease supports the involvement of specific protein processing, energy metabolism, and signaling pathways, and suggests novel disease mechanisms , 2005, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.
[65] L. Forno,et al. CONCENTRIC HYALIN INTRANEURONAL INCLUSIONS OF LEWY TYPE IN THE BRAINS OF ELDERLY PERSONS (50 INCIDENTAL CASES): RELATIONSHIP TO PARKINSONISM , 1969, Journal of the American Geriatrics Society.
[66] C. Scherzer. Chipping away at diagnostics for neurodegenerative diseases , 2009, Neurobiology of Disease.
[67] K. Jellinger. A critical evaluation of current staging of alpha-synuclein pathology in Lewy body disorders. , 2009, Biochimica et biophysica acta.